JPS60181024A - Composition for dermatologic administration - Google Patents

Composition for dermatologic administration

Info

Publication number
JPS60181024A
JPS60181024A JP59037637A JP3763784A JPS60181024A JP S60181024 A JPS60181024 A JP S60181024A JP 59037637 A JP59037637 A JP 59037637A JP 3763784 A JP3763784 A JP 3763784A JP S60181024 A JPS60181024 A JP S60181024A
Authority
JP
Japan
Prior art keywords
family
dried
case
composition
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP59037637A
Other languages
Japanese (ja)
Inventor
Mareyoshi Sawaguchi
希能 澤口
Isao So
宗 伊佐雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Electric Industrial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Electric Industrial Co Ltd filed Critical Nitto Electric Industrial Co Ltd
Priority to JP59037637A priority Critical patent/JPS60181024A/en
Publication of JPS60181024A publication Critical patent/JPS60181024A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:A composition for dermatologic administration containing at least one selected from dried bark of phellodendoron amurense RUPRECUT of the family Rutaceae and dried rhizome of Coptis Japonica MAKINO of the family Ranunculaceae and the dried whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae. CONSTITUTION:At least one of dried bark of Phellodendoron amurense RUPRECUT of the family Rutaceae and dried rhizome of coptis Japonica MAKINO of the family Ranunculaceae is blended with the dried whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae in a weight ratio of 1:10, preferably 1:2- 4 to give a composition for dermatologic administration to be added to a remedy for skin diseases, bothing agent, shampoo, soap, etc. An amount of each component in a base, etc. is 0.01-20wt% in case of dried powder of the whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae, 0.003-10wt% in case of extract of it, 0.01-10wt% in case of dried powder of dried bark of Phellodendoron amurense RUPRECUT of the family Rutaceae, 0.003-5wt% in case of extract of it, and an amount of dried rhizome of coptis Japonica MAKINO of the family Ranunculaceae is almost the same as that of dried bark of Phellodendoron amurense RUPERCUT of the family Ranunculaceae. A dose for remedy for trauma, humid tetter, etc. is 50-200mg in case of powder, and 5-20mg in case of extract.

Description

【発明の詳細な説明】 〔技術分野〕 本発明は、漢方生薬を主成分とする外皮投与用組成物、
特に外傷、湿疹等の外皮疾患の治療、予防に使用しうる
組成物に関する。
[Detailed Description of the Invention] [Technical Field] The present invention relates to a composition for dermal administration containing Chinese herbal medicine as a main component,
In particular, the present invention relates to a composition that can be used for the treatment and prevention of external skin diseases such as trauma and eczema.

〔従来技術〕[Prior art]

従来より外傷、湿疹等の皮膚疾患に対する治療剤として
非常に多くの合成系外用薬剤、例えばステロイド系消炎
剤、非ステロイド系消炎剤、局所麻酔剤、殺菌剤、殺真
菌剤などが市場に出ている。
A large number of synthetic external drugs such as steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, local anesthetics, bactericides, and fungicides have been on the market as therapeutic agents for skin diseases such as trauma and eczema. There is.

ところが、ステロイド剤などは連用すると副作用を伴っ
たり、局所麻酔剤、殺菌剤、殺真菌剤等はアレルギー症
状等を引き起こすなど、合成系薬剤は必ずしも好ましい
ものばかりではない。
However, synthetic drugs are not always preferable, as steroids and the like can have side effects if used repeatedly, and local anesthetics, bactericides, fungicides, and the like can cause allergic symptoms.

これに対し、中黄膏、紫雲膏などに代表される漢方系の
皮膚疾患治療剤は、アレルギー症状やその他の副作用が
極めて少なく、効果は緩やかながら確実なものが多い、
ところが、これら漢方系の外用剤は早期に痛みを止める
といった速効性の点においては非常に劣るものが少な(
ない。
On the other hand, Chinese herbal medicines for treating skin diseases, such as Zhonghuang-yang and Shiyun-yang, have extremely few allergic symptoms and other side effects, and their effects are gradual but certain.
However, most of these Chinese herbal medicines are extremely inferior in terms of their quick-acting ability to quickly stop pain (
do not have.

かかる実情下に、本発明者らは漢方生薬系のみで合成系
薬剤に匹敵する、皮膚患部に対する鎮痛作用、消炎作用
、抗菌作用、さらには局麻作用(鎮痛、止環作用等)を
合わせ持ち、かつアレルギー症状、その他の副作用の少
ない外皮投与用組成物を得るべ(研究を重ねたところ、
活性成分として、漢方生薬である黄柏及び黄速から選ば
れる少なくとも一種並びに白屈菜を併用して外皮投与せ
しめることにより、すり傷、切り傷、湿疹、発赤等に対
して、消炎作用、殺菌作用を示す他、局所麻酔作用(鎮
痛、止環作用)を示し、しかも副作用の少ないことを見
いだした。
Under these circumstances, the present inventors have developed a herbal herbal medicine system that has analgesic, anti-inflammatory, antibacterial, and local analgesic effects (analgesic, ring-stopping, etc.) on affected skin areas that are comparable to synthetic drugs. , and to obtain a composition for dermal administration with fewer allergic symptoms and other side effects (after repeated research,
The active ingredient is at least one selected from the Chinese herbal medicines Huangbai and Huangsu, and Chinese cabbage is administered to the skin to provide anti-inflammatory and bactericidal effects on abrasions, cuts, eczema, redness, etc. In addition to this, they also showed local anesthetic effects (analgesic and ring-locking effects), and also had few side effects.

本発明は、かかる知見に基づいて完成されたものであり
、黄柏及び黄連から選ばれる少なくとも一種及び白屈菜
を含有してなる外皮投与用組成物に関する。
The present invention was completed based on this knowledge, and relates to a composition for administration to the skin, which contains at least one selected from Oriental cypress and Oriental chinensis and Chinese cabbage.

本発明に用いる白屈菜は、ケシ科(Family Pa
ρ−averaceae )の植物、クサノオ(Che
lidonium tsa−jus L、 5ubsp
、 asoaticum It八へ^)の全草を乾燥し
たものである。白屈菜は微粉末又はメタノール、エタノ
ールなどのアルコール、アセトンなどのケトン、エーテ
ル、ヘンゼン等の有機溶媒で抽出し製した乾燥エキスか
、又は水にクエン酸、塩酸などを添加した酸性水で抽出
し製した乾燥エキスの形態で用いることが好ましい。
The Chinese cabbage used in the present invention belongs to the Papaveaceae family (Family Pa.
ρ-averaceae) plant, Che
lidonium tsa-jus L, 5ubsp
It is the dried whole plant of Asoaticum Ithahe^). White cabbage can be extracted with a fine powder or a dry extract extracted with an organic solvent such as alcohol such as methanol or ethanol, ketone such as acetone, ether, or Hensen, or with acidic water made by adding citric acid, hydrochloric acid, etc. to water. It is preferable to use it in the form of a prepared dry extract.

また、本発明に用いる黄柏は、ミカン科(Fami−1
y Rutaceae )の植物、キハダ(Phell
odendoronamurense RUPRECI
IT )の樹皮を乾燥したものである。黄柏は微粉末又
は水、メタノール、エタノールなどのアルコール、アセ
トンなどのケトン等の比較的極性の高い溶媒で抽出され
た乾燥エキスの形態で用いることが好ましい。
In addition, the yellow oak used in the present invention is of the family Rutaceae (Fami-1).
y Rutaceae) plant, yellowfin (Phell)
odendoronamurense RUPRECI
IT) is the dried bark of the tree. It is preferable to use the yellow oak in the form of a fine powder or a dry extract extracted with a relatively highly polar solvent such as water, alcohol such as methanol or ethanol, or ketone such as acetone.

黄連は、キンポウゲ科(Family Ranuncu
laceae)の植物、オウレン(Coptis Ja
powica M^KINO)の根茎を乾燥したもので
、黄連は微粉末又は水、メタノール、エタノールなどの
アルコール、アセトンなどのケトン等の比較的極性の高
い溶媒で抽出された乾燥エキスの形態で用いることが好
ましい。
Huangren is a family of Ranunculaceae (Family Ranunculaceae).
laceae) plant, Coptis Ja
powica M^KINO), and Huangren is used in the form of a fine powder or a dried extract extracted with a relatively polar solvent such as water, alcohol such as methanol or ethanol, or ketone such as acetone. It is preferable.

各成分の組成比は、黄柏(黄連)/白屈菜−1/10〜
10(就中、1/2〜4)が好ましい。
The composition ratio of each component is Huanglian/White cabbage - 1/10 ~
10 (particularly 1/2 to 4) is preferable.

本発明組成物における各成分は、いずれも古来から常用
されている漢方薬であり、その安全性はすでに確立され
ている。
Each component in the composition of the present invention is a Chinese herbal medicine that has been commonly used since ancient times, and its safety has already been established.

本発明の組成物は、皮膚疾患治療剤(就中、すり傷、切
り傷、湿疹等の治療剤)として使用され、また浴剤、シ
ャンプー、石鹸等に配合してこれらに殺菌性、消炎性、
止環性、鎮痛性をもたせるために使用される。
The composition of the present invention can be used as a therapeutic agent for skin diseases (in particular, a therapeutic agent for abrasions, cuts, eczema, etc.), and can also be added to bath salts, shampoos, soaps, etc. to have bactericidal, anti-inflammatory, and anti-inflammatory properties.
Used for ring-stopping and analgesic properties.

本発明組成物は、例えば、製薬上許容される担体、賦形
剤、希釈剤、基剤などの製薬用剤と混合して軟膏剤、液
剤などの形態とされる。また、従来の浴剤、石鹸、シャ
ンプー等に配合することによって、これらに殺菌性をも
たせることが可能である。
The composition of the present invention is mixed with pharmaceutical agents such as pharmaceutically acceptable carriers, excipients, diluents, and bases to form ointments, liquids, and the like. Furthermore, by adding it to conventional bath additives, soaps, shampoos, etc., it is possible to impart sterilizing properties to these.

軟膏剤の基剤としては、従来既知のものを用いればよく
、例えば、油性基剤(例、ゴマ油)、半油性基剤(例、
オリーブ油、ミツロウ、水、ショ糖の脂肪酸エステル系
などの乳化基剤)、水溶性基剤(例、マクロゴール、ア
クリルゲル系)がいずれも好適に使用されるが、一般的
には半油性基剤、水溶性基剤が好ましい。
As the base for the ointment, conventionally known bases may be used, such as oil bases (e.g. sesame oil), semi-oil bases (e.g.
Emulsifying bases such as olive oil, beeswax, water, and sucrose fatty acid esters) and water-soluble bases (e.g., macrogol, acrylic gels) are preferably used, but in general, semi-oily bases are used. A water-soluble base is preferred.

液剤用の基剤としては、好ましくは水、グリセリン、ア
ルコール(例、エタノール)の系ライ使用される。
As a base for liquid preparations, preferably water, glycerin, and alcohol (eg, ethanol) are used.

本発明組成物における基剤等への各成分の配合量は、次
の通りである。
The amount of each component added to the base etc. in the composition of the present invention is as follows.

白屈菜は基剤に対して、その乾燥粉末の場合、通富0.
O1〜20重景%、好ましくは0.5〜8重量%、その
エキスの場合、O,OO3〜10重量%、好ましくは0
.1〜5重量%である。
In the case of the dry powder of Chinese cabbage, the ratio of the base to the base is 0.
1-20% by weight of O, preferably 0.5-8% by weight, in the case of its extract, 3-10% by weight of O,OO, preferably 0
.. It is 1 to 5% by weight.

黄柏は基剤に対して、その乾燥粉末の場合、通寓0.0
1−10重量%、好ましくは0.1〜5重量%程度であ
り、そのエキスの場合、0.003〜5重量%程度、好
ましくは0.01〜2重量%程度である。
In the case of its dry powder, the ratio of Huangbai to the base is 0.0.
It is about 1-10% by weight, preferably about 0.1-5% by weight, and in the case of its extract, about 0.003-5% by weight, preferably about 0.01-2% by weight.

黄連の配合量は、黄柏とほぼ同程度でよい。The amount of Huanglian added may be approximately the same as that of Huangbai.

本発明組成物を、例えば外傷、湿疹等の治療に使用する
場合、その投与量はその粉末の場合は通寓、50〜20
0蒙g2エキスの場合は、5〜20mgである。投与回
数は、1日1〜3回の範囲で適宜選択しうる。
When the composition of the present invention is used, for example, for the treatment of trauma, eczema, etc., the dosage is generally 50 to 20 mg in the case of powder.
In the case of 0 Mong2 extract, it is 5 to 20 mg. The frequency of administration can be appropriately selected within the range of 1 to 3 times a day.

以下、実施例、実験例によって本発明をより具体的に説
明すると共に、本発明の効果を明確にする。
EXAMPLES Hereinafter, the present invention will be explained more specifically using Examples and Experimental Examples, and the effects of the present invention will be clarified.

なお、以下の実施例および比較例における生薬類のg数
は基剤(ベース)100gに対しての配合量を表わす。
In addition, the number of grams of crude drugs in the following Examples and Comparative Examples represents the amount blended with respect to 100 g of base.

実施例1 第10改正日本薬局方収載の親水軟膏(基剤)に対し、
白屈菜粉末5g及び貧相粉末2gを配合して軟膏を得た
Example 1 For hydrophilic ointment (base) listed in the 10th revised Japanese Pharmacopoeia,
An ointment was obtained by blending 5 g of white cabbage powder and 2 g of white powder.

実施例2 実施例1で用いた親木軟膏(基剤)に対し、白屈菜粉末
5g及び黄連粉末2gを配合して軟膏を得た。
Example 2 An ointment was obtained by blending 5 g of Chinese cabbage powder and 2 g of Huanglian powder with the parent tree ointment (base) used in Example 1.

実施例3 実施例Iで用いた親木軟膏(基剤)に対し、黄柏エタノ
ールエキス4g及び白屈菜1%クエン酸エキス2gを配
合して軟膏を得た。
Example 3 An ointment was obtained by blending 4 g of Huangbo ethanol extract and 2 g of 1% citric acid extract of Chinese cabbage with the parent tree ointment (base) used in Example I.

実施例4 エタノール 10g グリセリン 20g プロピレングリコール 5g 精製水 65g 上記の液剤基剤に対し、白屈菜エタノールエキス2g及
び黄連水製エキス2gを含有せしめて液剤を得た。
Example 4 Ethanol 10g Glycerin 20g Propylene glycol 5g Purified water 65g The above liquid preparation base was made to contain 2 g of Chinese cabbage ethanol extract and 2 g of Huang Rensui extract to obtain a liquid preparation.

比較例1 実施例1において白屈菜粉末を除去し、黄柏粉末7gと
した軟膏を得た。
Comparative Example 1 In Example 1, the white cabbage powder was removed to obtain an ointment containing 7 g of Huangbao powder.

比較例2 実施例2の処方から黄連粉末を除去し、白屈菜を7gと
した軟膏を得た。
Comparative Example 2 Huanglian powder was removed from the formulation of Example 2 to obtain an ointment containing 7 g of Chinese cabbage.

実験例1 実施例及び比較例の製剤を、第1表に明示し起疾患に局
所投与し、その治癒に要する平均日数(13例)を開べ
てその結果を第1表に示した。
Experimental Example 1 The formulations of Examples and Comparative Examples are shown in Table 1 and locally administered to the affected disease, and the average number of days required for healing (13 cases) is shown in Table 1.

第1表 数字はマウスの治癒までの平均日数 以上の実施例により、本発明組成物が優れたものである
ことが立証される。
The numbers in Table 1 are more than the average number of days taken for mice to heal, which proves that the composition of the present invention is excellent.

Claims (1)

【特許請求の範囲】[Claims] 黄柏及び黄速から選ばれる少なくとも一種及び白屈菜を
含有してなる外皮投与用組成物。
A composition for rind administration, comprising at least one selected from Huangbo and Huangsu and Chinese cabbage.
JP59037637A 1984-02-28 1984-02-28 Composition for dermatologic administration Pending JPS60181024A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59037637A JPS60181024A (en) 1984-02-28 1984-02-28 Composition for dermatologic administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59037637A JPS60181024A (en) 1984-02-28 1984-02-28 Composition for dermatologic administration

Publications (1)

Publication Number Publication Date
JPS60181024A true JPS60181024A (en) 1985-09-14

Family

ID=12503157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59037637A Pending JPS60181024A (en) 1984-02-28 1984-02-28 Composition for dermatologic administration

Country Status (1)

Country Link
JP (1) JPS60181024A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661330A1 (en) * 1990-02-07 1991-10-31 Azoulay Marlene Compound permitting manicure and pedicure treatments and the treatment of corns, calluses and verrucae
EP0606786A2 (en) * 1993-01-15 1994-07-20 Rongxiang Xu A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661330A1 (en) * 1990-02-07 1991-10-31 Azoulay Marlene Compound permitting manicure and pedicure treatments and the treatment of corns, calluses and verrucae
EP0606786A2 (en) * 1993-01-15 1994-07-20 Rongxiang Xu A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human
EP0606786A3 (en) * 1993-01-15 1995-04-05 Rongxiang Xu A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human.

Similar Documents

Publication Publication Date Title
Kriplani et al. Arnica montana L.–a plant of healing
RU2361601C2 (en) Composition for treatment of atopic dermatitises, allergic conditions of skin and blackhead
US5080901A (en) Cosmetic and paramedicinal compositions containing plant extracts
US20090123564A1 (en) Novel compositions for hair disorders and process of preparation thereof
KR20110082292A (en) Antipuritis and antiance effects of dendropanax morbifera lev. extract
Gardiner Chamomile (Matricaria recutita, Anthemis nobilis)
JP2609564B2 (en) Cream for allergic dermatitis and method for producing the same
WO2011105839A2 (en) External skin composition and a production method therefor
US10780141B2 (en) Herbal combinations for treating eczema
KR20090084435A (en) Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of houttuynia cordata thub and ulmus davidana var.japonica as an active ingredient
DE602004005183T2 (en) PHARMACEUTICAL COMPOSITIONS USING EXTRACT FROM EUPHORBIA PROSTRATA
US20170049687A1 (en) Herbal Combinations For Treating Scalp Conditions
EP1399173A2 (en) Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor
KR20030055154A (en) A composition for treating a dermatitis and a method of preparing the same
Deka et al. Mechanism of action of wound healing activity of Calendula officinalis: a comprehensive review
KR20040041912A (en) Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition
EP0348215B1 (en) Novel cosmetic and paramedicinal compositions
JPS60181024A (en) Composition for dermatologic administration
EA033620B1 (en) Medical formulation for prevention and treatment of psoriasis
US20160375076A1 (en) Herbal Combinations for Treating Eczema
KR20110079088A (en) Cosmetic composition containing purified catechin for atopic dermatitis
KR20070033133A (en) A composition for external preparation for the protection and the treatment of atopic dermatitis
KR20030092519A (en) Composition for improving or preventing of allergic dermatological diseases
Panda Extraction, formulation and evaluation of antiaging curcumin facial cream
KR0165938B1 (en) Hair growth stimulating composition containing extract of artemisia apiaceahance